FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:929-939 February 28, 2008 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the clinician, systemic lupus erythematosus is important because it is a potentially fatal disease that is easily confused with many other disorders. To the immunologist, lupus is intriguing because all the key components of the immune system are involved in the underlying mechanisms of the disease. This review describes these mechanisms and shows how knowledge of the pathogenesis of lupus facilitates its treatment.

The prevalence of lupus ranges from approximately 40 cases per 100,000 persons among Northern Europeans to more than 200 per 100,000 persons among blacks.¹ In the United States, the number of patients with lupus exceeds 250,000. . . . [Full Text of this Article]

Genetic and Epidemiologic Factors

Autoantibodies in Lupus

Tissue Damage by Autoantibodies in Lupus

The Role of T Cells

Source of the Autoantigens in Lupus

Cytokines in Lupus

Implications for Treatment

Summary

Source Information

From the Centre for Rheumatology Research, Division of Medicine, University College London, London.

Address reprint requests to Dr. Isenberg at the Centre for Rheumatology Research, Division of Medicine, University College London, Rm. 331, 3rd Fl., 46 Cleveland St., London W1T 4JF, United Kingdom, or at d.isenberg@ucl.ac.uk.

This article has been cited by other articles:

• (2008). Unraveling the Genetic Predisposition to Systemic Lupus Erythematosus. Journal Watch Dermatology 2008: 1-1 [Full Text]